An observational study in Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms and Carcinoma, Bronchogenic, sponsored by Wenzhou Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-01.
Sponsored by Wenzhou Medical University · Observational
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 200 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Wenzhou Medical University is the lead sponsor of 93 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
NSCLC patients with activating EGFR mutations
Exclusion Criteria:
dynamic changes of circulating tumor DNA in late stage NSCLC patients under Gefitinib treatment
Time frame: 2 years
Plan to share: Undecided
This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wenzhou Medical University